These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Kim DS; Lee SH; Kim JS; Lee SC; Kwon MH; Kim YS Biochem Biophys Res Commun; 2009 Feb; 379(2):314-8. PubMed ID: 19103171 [TBL] [Abstract][Full Text] [Related]
25. Recombinant antibody technology: its advent and advances. Hozumi N; Sandhu JS Cancer Invest; 1993; 11(6):714-23. PubMed ID: 8221205 [No Abstract] [Full Text] [Related]
26. Bispecific antibodies for cancer therapy. Chames P; Baty D Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873 [TBL] [Abstract][Full Text] [Related]
27. Design and manufacture of monoclonal antibodies for radioimmunotherapy. Hale G; Berrie E; Bird P Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):258-66. PubMed ID: 15640789 [TBL] [Abstract][Full Text] [Related]
29. Antibody engineering: facing new challenges in cancer therapy. Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728 [TBL] [Abstract][Full Text] [Related]
30. The rapid discovery of engineered antibodies. Wang M; He M IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332 [TBL] [Abstract][Full Text] [Related]